Dear Lab Tests OnlineAU community,
You are invited to participate in a survey focused on users’ perceptions of the Lab Tests Online Australasia website which we have developed in collaboration with Curtin University. Your feedback will assist us to improve the website and better support the general public’s and health professionals’ understanding about pathology lab tests. This survey should take about 5-7 minutes to complete. Participation is completely voluntary and all the information you provide will be anonymous.
Lab Test OnlineAU Team
Centromere antibody; ACA
To detect the presence of anticentromere antibodies; to help diagnose limited systemic sclerosis (previously termed limited scleroderma)
When you have one or more symptoms that suggest limited systemic sclerosis (previously known as CREST syndrome or limited scleroderma)
A blood sample drawn from a vein in your arm
The anticentromere antibody (ACA) is an autoantibody - a protein produced by the immune system that mistakenly targets the body's own tissues. More specifically, it is one of several antinuclear antibodies and it targets the centromere, a component of the chromosomes found in the nucleus of the body's cells. The ACA test detects and measures the amount of anticentromere antibody in the blood to help diagnose a form of systemic sclerosis (scleroderma).
Systemic sclerosis is a group of rare connective tissue disorders. There are two distinct subtypes: diffuse cutaneous systemic sclerosis that affects the entire body and limited cutaneous systemic sclerosis. These subsets of systemic sclerosis are defined on the basis of the extent of skin involvement. ACA is found in about 60 - 80 per cent of people who have limited systemic sclerosis. Only about 5 per cent of patients with diffuse systemic sclerosis have ACA.
Limited systemic sclerosis is typically associated with one or more symptoms that were known collectively as CREST syndrome (although this term is no longer in wide medical use). CREST symptoms include:
Anticentromere antibody can be present in up to 95 per cent of people who have CREST symptoms.
A blood sample is obtained by inserting a needle into a vein in the arm.
No test preparation is needed.
An anticentromere antibody (ACA) test is primarily ordered to help diagnose systemic sclerosis (scleroderma). The test may be used to distinguish between this and other conditions with similar symptoms.
Testing may be used to provide the doctor with additional information if an ANA (antinuclear antibody) test is positive, especially if the test produces a speckled, nucleolar, or centromere pattern. (For more on this, see "What does the test result mean?" in the ANA article.)
It may be ordered along with Scl-70 (anti-topoisomerase), another autoantibody that may be present with scleroderma.
An ACA test may be ordered along with other tests for autoantibodies, including ANA.
An ACA test may be ordered when a person has a positive result on an ANA test and one or more of the CREST symptoms. These symptoms include:
If a person is positive for ACA and has CREST symptoms, it is likely they have limited systemic sclerosis. ACA is found in about 60 - 80 per cent of people who have limited systemic sclerosis.
If a person is negative for ACA, it is likely that their symptoms are due to another condition. However, it is possible, though rare, that they have limited systemic sclerosis and do not produce anticentromere antibodies.
ACA can be positive in some other autoimmune disorders, such as systemic lupus erythematosus (lupus), rheumatoid arthritis, or primary biliary cirrhosis.
Typically, only people who have CREST symptoms are tested for ACA. However, some people may be positive for ACA prior to the development of these symptoms and ACA may be performed in conjunction with testing for other autoimmune disorders.
The amount of ACA present does not, in general, correlate to the severity of a person's symptoms.
This test is not intended to be a general screening test. It is typically only indicated when a person has one or more CREST symptoms. Since limited systemic sclerosis is relatively rare, most people will never need to have this test performed.
In general, no, it does not respond to lifestyle changes.
Concentrations of ACA in the blood may vary over time but once a person has developed ACA, he will continue to produce it.
No. ACA testing requires specialized equipment and training. It is not offered by every laboratory and will usually need to be sent to a reference laboratory.
ANA, Autoantibodies, ENA Panel
Conditions: Scleroderma, Autoimmune Disorders
Healthdirect Australia - Scleroderma
American Academy of Family Physicians: Scleroderma (USA)
MedlinePlus Medical Encyclopedia: Scleroderma (USA)
National Institute of Arthritis and Musculoskeletal and Skin Disease: Handout on Health - Scleroderma (USA)
Scleroderma Research Foundation (USA)
International Scleroderma Network: Antibodies in Systemic Scleroderma (USA)
Scleroderma Care Foundation: What You Should Know About The AntiNuclear Antibody Or ANA Test (USA)
Additional information: Sources
Last Review Date: March 15, 2016